ライフサイエンスコーパス: pseudotype

1 had a minimal inhibitory effect on the E2-G pseudotype.

2 activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes.

3 of infection based on envelope glycoprotein pseudotypes.

4 ectious particles through a process known as pseudotyping.

5 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 36 serum samples tested had a neutrali

6 ctions of recombinant adeno-associated virus pseudotype 2/5 to overexpress wildtype human alpha-synuc

7 nd self-complementary adeno-associated virus pseudotype 2/9 (AAV2/9) to transduce the nervous system

8 d entry kinetics of native viruses and their pseudotyped analogs.

9 length HIV-1(YU2)/vesicular stomatitis viral pseudotype and injected into basal ganglia of syngeneic

10 promoters to target retrograde infection of pseudotyped and genetically modified rabies virus eviden

11 ng antibodies against infection by divergent pseudotyped and live MERS-CoV strains, as well as antibo

12 highest-affinity MAb, m336, neutralized both pseudotyped and live MERS-CoV with exceptional potency,

13 vity by conferring infectivity on retroviral pseudotypes and triggering cell-cell fusion.

14 d mechanistic analysis performed using virus pseudotypes and virus-like particles.

15 ainst human immunodeficiency virus (HIV)-HCV pseudotype, and 10 of 36 serum samples tested had a neut

16 hibited IC(50) values of less than 5 nM in a pseudotyped antiviral assay, and compound 13k was demons

17 Cloning of the gene for an ex vivo pseudotype assay showed fusogenicity on both dog and cat

18 sion vector for ex vivo cell-cell fusion and pseudotype assays demonstrated fusogenicity on a large p

19 iated cleavage and thus inhibit the entry of pseudotypes bearing the glycoprotein derived from SARS-C

20 coprotein pseudotyped viruses but not by the pseudotypes bearing the glycoprotein of vesicular stomat

21 In contrast, pLV pseudotyped both glycoproteins efficiently; however, muc

22 TB1 enhanced transduction with various pseudotypes but without inducing the autophagy process.

23 ate infection, in conjunction with smCD4, by pseudotypes carrying Envs from multiple SIVsmm subtypes.

24 iated robust entry into transfected cells by pseudotypes carrying SIVagmSab92018ivTF Env, with lower-

25 , in contrast to VSV-G, mature BASV-G in VSV pseudotypes consists of a mixture of high-mannose and co

26 We produced VSV pseudotypes containing the prototypical X-31 (H3) HA, ei

27 Additional experiments indicated that pseudotyping contributed to the elevated polytropic viru

28 ftable C17.2 neural stem cells engineered to pseudotype, disseminate, and trans-complement neurovirul

29 In this study, the pseudotyped doubly labeled fluorescent reporter red/gree

30 ette can be packaged in different AAV capsid pseudotypes, each having a unique transduction profile.

31 rexpression of these ISGs does not block HCV pseudotype entry into Huh7 cells.

32 th a replication-defective HIV vector with a pseudotype envelope.

33 e molecules varies, depending on the type of pseudotyping envelope proteins.

34 ecombinant vesicular stomatitis virus (rVSV) pseudotypes expressing Ebolavirus glycoproteins (GPs) in

35 of marker genes; control of synaptic spread; pseudotyping for infection of selected cells; addition o

36 protein (BASV-G) can be successfully used to pseudotype glycoprotein-deficient vesicular stomatitis v

37 nutoides cells are also infectible with LacZ pseudotypes having AKV Env and Moloney MLV (MoMLV) Gag p

38 o establish infection we used HCV lentiviral pseudotypes (HCVpp) and demonstrated a defect in cell en

39 ither human immunodeficiency virus (HIV)-HCV pseudotypes (HCVpp) nor HIV and Dengue virus (DENV) infe

40 s and enhanced the cell entry of both SARS S-pseudotyped HIV and authentic SARS-CoV.

41 ect on human immunodeficiency virus (HIV) GP pseudotyped HIV or adeno-associated virus 2 vector entry

42 Using Ebola Zaire GP-pseudotyped HIV particles bearing a luciferase reporter

43 rameshift efficiency, and infectivity, using pseudotyped HIV-1 and HEK293T cells.

44 Env protein by the viral protease in MLV Env-pseudotyped HIV-1 particles bearing the MA mutations and

45 ll enhancing elements combined, the titer of pseudotyped HIV-1 particles reached almost 10(6) infecti

46 HIV-1 or murine leukemia virus Env (MLV-Env)-pseudotyped HIV-1 particles was enhanced in IFN-alpha-tr

47 or expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication was also blocked by IL-12/

48 pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clini

49 d not lead to increased infection with VSV-G-pseudotyped HIV-1 vectors.

50 and they strongly inhibit the infectivity of pseudotyped HIV-1 virions.

51 V-2 Spike glycoprotein for the generation of pseudotyped HIV-1, murine leukemia virus (MLV), and vesi

52 ansfection production of a Sendai virus F/HN-pseudotyped HIV-1-based third generation lentiviral vect

53 ular stomatitis virus G glycoprotein (VSV-G)-pseudotyped HIV-1.

54 had greater susceptibility to infection with pseudotyped HIV.

55 nfirmed that Tat expression and infection of pseudotyped HIV.GFP led to increased lysosomal exocytosi

56 onnative viral particles in a process termed pseudotyping; however, the molecular mechanisms governin

57 The titers of WEEV GP-pseudotyped human immunodeficiency virus type 1 (HIV) ra

58 We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1 (HIV-1)

59 h amplification on complementing cell lines, pseudotyping if desired, purification by ultracentrifuga

60 Having determined that this pseudotyping increased the efficiency of gene transfer t

61 in a SARS coronavirus (CoV) and Ebola virus-pseudotype infection assay with the oxocarbazate but not

62 potency of inhibitors observed in the virus pseudotype infection assay.

63 iral activity of these compounds in an Ebola pseudotyped infection model was in the low micromolar ra

64 ded compounds with subnanomolar potency in a pseudotype infectivity assay and good pharmacokinetic pr

65 of vesicular stomatitis virus (VSV)/HCV E1-G pseudotype infectivity by antibodies to apolipoprotein E

66 n apolipoprotein B (ApoB), with VSV/HCV E2-G pseudotype infectivity remaining largely unaffected.

67 yed approximately 50% neutralization of E1-G pseudotype infectivity.

68 We have produced a pseudotyped influenza virus based on suppression of the

69 nerate highly concentrated lentiviral vector pseudotypes involving different envelope glycoproteins.

70 Virus pseudotyping is a useful and safe technique for studying

71 Although pseudotyping is widely used for engineering chimeric vir

72 Despite the fact that viral pseudotyping is widely used, what makes a virus/glycopro

73 However, this process, termed pseudotyping, is poorly understood at the molecular leve

74 did not exhibit a comparable high titer upon pseudotyping, it led to a significant increase in distal

75 rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors infection in LC.

76 is virus envelope glycoproteins (WEEV GP) to pseudotype lentiviral vectors.

77 oglobulin G levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever

78 ular stomatitis virus glycoprotein G (VSV-G)-pseudotyped lentiviral gene therapy vector could also in

79 wing transduction of T cell lines with VSV-G-pseudotyped lentiviral or gammaretroviral particles.

80 ly impaired entry of genotype 1a HCV and HCV-pseudotyped lentiviral particles (HCVpp) in Huh-7 cells

81 We found that the VSV-G-pseudotyped lentiviral vector failed to fuse to resting

82 ified gibbon ape leukemia virus glycoprotein-pseudotyped lentiviral vector infectivity of HSPCs, the

83 ped a novel targeting Sindbis virus envelope pseudotyped lentiviral vector, 2.2ZZ, which acquires spe

84 When pseudotyped lentiviral vectors encoding green fluorescen

85 fuse to resting CD4(+) T cells while HIV Env-pseudotyped lentiviral vectors fused, reverse transcribe

86 Rabies pseudotyped lentiviral vectors have great potential in g

87 as the major entry port of VSV and of VSV-G-pseudotyped lentiviral vectors in human and mouse cells,

88 sed to the cytoplasmic tail (CT) of gp41 and pseudotyped lentiviral vectors with them.

89 us neutralization activity was analyzed with pseudotyped lentiviral vectors, and antibody epitope map

90 Using pseudotyped lentiviral vectors, we found that a soluble

91 ral receptor TVB (TVB-NRG1), along with EnvB pseudotyped lentivirus (LV) and rabies virus (RV), to se

92 l ACE2 receptor traps neutralized SARS-CoV-2-pseudotyped lentivirus and authentic SARS-CoV-2 virus wi

93 date, NIH-CoVnb-112, blocks SARS-CoV-2 spike pseudotyped lentivirus infection of HEK293 cells express

94 ransfer of Nipah virus envelope glycoprotein-pseudotyped lentivirus particles by MDCs were severely a

95 antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-C

96 Neonatal intravascular injection of VSV-G pseudotyped lentivirus resulted in almost exclusive tran

97 h are predominantly quiescent, by generating pseudotyped-lentivirus.

98 eutralizing variant hemagglutinin-expressing pseudotyped lentiviruses.

99 tion by vesicular stomatitis virus G protein pseudotyped M-PMV.

100 These findings indicate the utility of VSVG-pseudotyped MLV for transgenesis of S. mansoni, herald a

101 Using CERV2 Env-pseudotyped MLV reporters, we identified copper transpor

102 (ancHTenv) that could support infection of a pseudotyped modern gammaretrovirus.

103 ogs fail to support viral entry/infection of pseudotyped murine leukemia viruses expressing pathogeni

104 Moreover, serology testing based on BASV-G pseudotype neutralization can be used to uncover the pre

105 We suggest that pseudotyping occurs through specific lipid-protein inter

106 eat the different rates of degeneration, two pseudotypes of recombinant adeno-associated virus (AAV)

107 n of mice with an ecotropic virus results in pseudotyping of intact endogenous viruses that have not

108 provided via selection of glycoproteins for pseudotyping of the lentiviral particles.

109 Furthermore, pseudotyping of the polytropic MuLV genome within ecotro

110 Marked amplification and pseudotyping of the polytropic MuLV were also observed i

111 ll Host & Microbe, three papers describe the pseudotyping of vesicular stomatitis virus (VSV) with th

112 This process of complementation, known as pseudotyping, often can occur even when the glycoprotein

113 ing cell-culture HCV 1a(H77)/2a chimera, HCV pseudotype particles (HCVpp) H77, and HCVpp HCV-1 after

114 Each HMAb broadly neutralizes retroviral pseudotype particles expressing HCV E1 and E2 glycoprote

115 lycoprotein sequences were tested in the HCV pseudotyped particles (HCVpp) system.

116 gth NiV-G, resulted in optimal titers of NiV-pseudotyped particles (NiVpp) ( approximately 10(6) IU/m

117 HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus glycopro

118 ne leukemia virus (MLV) Env can readily form pseudotyped particles with many retroviruses, suggesting

119 viruses to form infectious virions known as pseudotyped particles.

120 pe 1 (HIV-1) in the production of infectious pseudotyped particles.

121 ry suggested a significant reduction in E1-G pseudotype plaque numbers ( approximately 70%) by inhibi

122 We tested pseudotyped rAAVs of several common serotypes (rAAV 2/1,

123 Using pseudotyped rabies virus in a transgenic Gpr151-Cre mous

124 rons were susceptible to infection with EnvA-pseudotyped rabies virus in tumor virus A receptor trans

125 oped vesicular stomatitis virus glycoprotein-pseudotyped replication-defective simian immunodeficienc

126 We report that pseudotyped, replication-incompetent retroviruses can be

127 hepatocytes was examined directly using HCV-pseudotyped retroviral particles (HCV-pp).

128 nvelopes between PERV-A and PERV-C and using pseudotyped retroviral vectors to map the human cell tro

129 Rabbit anti-GBV-C E2 Abs neutralized HIV-1-pseudotyped retrovirus particles but not HIV-1-pseudotyp

130 e binding of soluble CD81 to immobilized HCV-pseudotyped retrovirus particles.

131 g but that OCEV glycoprotein precursor (GPC)-pseudotyped retroviruses poorly entered 53 human cancer

132 y resistant to infection by flaviviruses and pseudotyped retroviruses, but infection can be restored

133 or inhibited GP(1,2)-mediated cell entry of pseudotyped retroviruses.

134 or the M2 proton pump, inhibits entry of HA-pseudotyped retroviruses.

135 We generated high titers of GP-pseudotyped rLCMVDeltaGP/GFP via genetic trans complemen

136 Replication of these GP-pseudotyped rLCMVDeltaGP/GFP viruses was restricted to G

137 Using GP-pseudotyped rLCMVDeltaGP/GFP, we have also obtained evid

138 Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in 293 cells express

139 We infused a single dose of a serotype-8-pseudotyped, self-complementary adenovirus-associated vi

140 tion of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human i

141 The data support F/HN-pseudotyped SIV as a promising vector for pulmonary gene

142 Pseudotyping SIVmac/HIV-1 overcame this deficiency, sugg

143 ls primed with dendritic cells transduced by pseudotyped SIVs expressing high levels of IFN-gamma had

144 roblasts with a vesicular stomatitis virus G-pseudotyped strain of HIV-1 produced similar results, su

145 n antifiloviral screening system, based on a pseudotyping strategy, and its application in the discov

146 HLA-DR receptor as an entry mediator for H17 pseudotypes, suggesting that H17N10 possesses zoonotic p

147 The HSV pseudotyping system established in this study presents a

148 ur knowledge, this is the first time the VSV pseudotyping system has been successfully extended beyon

149 This HSV pseudotyping system pioneered in this work opens doors f

150 e using a human immunodeficiency virus-based pseudotyping system to identify specific regions that af

151 e development and optimization of a suitable pseudotyping system.

152 -expressing vesicular stomatitis virus (VSV) pseudotype that contained the NiV fusion (F) and attachm

153 ycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG.

154 Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a

155 While MMLV pseudotyped the vesicular stomatitis virus G glycoprotei

156 the potential benefits which may arise from pseudotyping the HIV-1 lentiviral vector with its homolo

157 DC-directed specificity is achieved through pseudotyping the vector with an engineered Sindbis virus

158 ses from cDNA, amplification of the viruses, pseudotyping them with EnvA or EnvB and concentration an

159 We suggest that these two regions dictate pseudotyping through interactions with specific lipid en

160 Using pseudotyping to assess Env function in single-round infe

161 ransfer comparable with that of AAV2 using a pseudotype vector (AAV2/5) at a 100-fold lower dose, our

162 ion significantly increased EBOV GP and VSVG pseudotyped vector transduction but had minimal effect o

163 tion of vesicular stomatitis virus GP (VSVG) pseudotyped vector.

164 Those pseudotype vectors contained no additional attenuating m

165 Our first aim was to utilize AAV pseudotype vectors, containing the genetic elements of t

166 RV-G pseudotyped vectors were co-transported with both the te

167 subsequently show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model

168 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glyc

169 eudotyped retrovirus particles but not HIV-1-pseudotyped vesicular stomatitis virus particles, and E2

170 ermore, expression of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homoty

171 h wild-type PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

172 EV S1(A), and infectivity assays with BCoV-S-pseudotyped vesicular stomatitis viruses.

173 Pseudotyped viral entry levels primarily corroborated th

174 coexpressed with GhV-G protein, and mediates pseudotyped viral particle entry.

175 as a mechanism of uptake of EBOV GP and VSVG pseudotyped viral particles.

176 property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene t

177 VSV and for the broad applicability of VSV-G-pseudotyped viral vectors for gene transduction.

178 SARS-CoV S, followed by cell-cell fusion and pseudotyped virion infectivity assays, showed a critical

179 Moreover, pseudotyped virions carrying these N-glycan mutants had

180 , inhibited SARS-CoV S-mediated entry of the pseudotyped virions in 293T cells expressing a functiona

181 Entry of pseudotyped virions required a gD receptor and was inhib

182 that membrane fusion during the entry of the pseudotyped virions shares common requirements with the

183 idate genes were identified by using EBOV GP pseudotyped virions to transduce human tumor cell lines

184 try for Ebola virus (EBOV) glycoprotein (GP) pseudotyped virions, we used comparative gene analysis t

185 the G614 variant grows to a higher titer as pseudotyped virions.

186 urine leukemia virus Env cytoplasmic tail in pseudotyped virions.

187 can affect VCA analyses, particularly using pseudotyped virions.

188 cathepsin L that blocked SARS-CoV and Ebola pseudotype virus entry in human cells.

189 Epitope characterization was performed using pseudotype virus expressing mutagenized rabies glycoprot

190 Using Env pseudotype virus infection assays, we found that deletin

191 rmed by antigen ELISA, as well as rabies and pseudotype virus neutralization.

192 Using pseudotype virus-based high-throughput screens, we have

193 ll-molecule compound libraries utilizing the pseudotype virus.

194 ratory syndrome (SARS) coronavirus and Ebola pseudotype virus.

195 ck spike protein binding and/or infection by pseudotyped virus and authentic SARS-CoV-2 virus.

196 We show that SARS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-2 infections are

197 We show that VSV-G-pseudotyped virus cannot fuse to unstimulated cells beca

198 eletion of RFC were nonpermissive for TG35-2-pseudotyped virus infection, but the introduction of fel

199 chloroquine, as highly active inhibitors of pseudotyped virus infection.

200 oV-2 S protein and efficiently supported the pseudotyped virus infection.

201 nd C HIV-1 strains, synergistically in a Env-pseudotyped virus neutralization assay.

202 easurements with NAb activity measured using pseudotyped virus particles, which offer the most inform

203 er, neutralisation capacity can differ among pseudotyped virus platforms.

204 In summary, pLV-S pseudotyped virus provides a valid screening tool for th

205 d single round vescicular stomatitis virus-G pseudotyped virus replication, whereas superinfection of

206 eutralisation were greater for the VSV-based pseudotyped virus system, which is particularly importan

207 entified a new FeLV Env (TG35-2) gene from a pseudotyped virus that does not belong to any known subg

208 R followed by cloning of env genes to create pseudotyped virus to explore the link between genotypic

209 RFC cDNAs conferred susceptibility to TG35-2-pseudotyped virus when introduced into nonpermissive cel

210 l receptor TVB fused to NRG, along with EnvB-pseudotyped virus, is able to direct infection selective

211 PR15, to a lesser extent, supported entry of pseudotype viruses bearing SIVagm envelopes, including S

212 Pseudotype viruses expressing glycoprotein from lyssavir

213 oprotein (EBOV-GP) gene was used to generate pseudotype viruses for screening of chemical libraries.

214 E2 antibody titers and neutralization of HCV pseudotype viruses similar to those with WT E1E2.

215 tically and geographically diverse HIV-1 Env-pseudotyped viruses and chronic infection plasma samples

216 The difference in sensitivity between pseudotyped viruses and primary isolates varied from 3-

217 cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion.

218 tent neutralization against EBOV and SUDV GP pseudotyped viruses as well as authentic pathogens, and

219 l of reference Env clones from among 219 Env-pseudotyped viruses assayed in TZM-bl cells with sera fr

220 the infection by EBOV and EBOV glycoprotein pseudotyped viruses but not by the pseudotypes bearing t

221 Pseudotyped viruses can be used as alternatives to live

222 ing using human immunodeficiency virus-based pseudotyped viruses expressing EBOV-GP.

223 00 well-characterized clade C envelope (Env)-pseudotyped viruses from early infection.

224 he small molecule inhibited the entry of all pseudotyped viruses in vitro and the cleavage of SARS-Co

225 9 was active against 636 different HIV-1 Env-pseudotyped viruses of varying tropism and derived from

226 tested was significantly reduced compared to pseudotyped viruses panels.

227 tibody, 10E8V2.0/iMab, neutralized 118 HIV-1 pseudotyped viruses tested with a mean 50% inhibitory co

228 Studies of entry performed with HTLV-3 Env-pseudotyped viruses together with SU binding studies rev

229 icular stomatitis virus glycoprotein (VSV-G)-pseudotyped viruses were generated by cotransfecting 293

230 from 200 southern African, clade C envelope-pseudotyped viruses with neutralization titers against 1

231 ese VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively.

232 V strains has mostly been measured using Env-pseudotyped viruses, which overestimate bNAb coverage an

233 pic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses.

234 icles (VLPs) as well as infectivity of GP1,2-pseudotyped viruses.

235 rnal region (MPER), using a panel of 125 Env-pseudotyped viruses.

236 for neutralizing activity using 36 HIV-1 Env-pseudotyped viruses.

237 idually by analyzing infectivity assays with pseudotyped viruses.

238 mes and subsequently replicate and spread as pseudotyped viruses.

239 face severely impairs the infectivity of Env-pseudotyped viruses.

240 le for viral infection or the release of H18-pseudotyped viruses.

241 canine MDCK II cells are susceptible to H17-pseudotyped viruses.

242 itro neutralizing activity against HIV-1 Env pseudotyped viruses.

243 arge, multi-subtype panel of 30 tier 2-3 Env-pseudotyped viruses.

244 gle-cycle assay against a large panel of Env-pseudotyped viruses.

245 Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported here could

246 y high efficiency regardless of the envelope pseudotype while scAAV9 mediates gene delivery to 40% of

247 uld reduce the gene transfer inoculum of the pseudotype while still achieving gene transfer comparabl

248 We generated here high-titer LVs pseudotyped with a baboon retroviral envelope glycoprote

249 eover, Ad-5/3-kappaBF512HRE, a viral variant pseudotyped with a chimeric 5/3 fiber, exerted a strong

250 Virions, pseudotyped with a class II, SFV E1 or VEEV E, or a clas

251 d improved photoreceptor transduction by Ad5 pseudotyped with Ad35 (Ad5/F35) or Ad37 (Ad5/F37) fiber

252 A recombinant AAV2 vector pseudotyped with an HBoV1 capsid has been developed to e

253 Jurkat cells infected by single-cycle HIV-1 pseudotyped with an HIV-1 envelope (Env) glycoprotein, b

254 However, the infectivity of HIV-1 pseudotyped with an MLV Env with the cytoplasmic tail fr

255 protein (GFP)-expressing proviral construct pseudotyped with CCR5-tropic or CXCR4-tropic envelope to

256 ocytes were resistant to hepatitis D viruses pseudotyped with CSHBV surface proteins.

257 compare the transduction efficiency of IDLVs pseudotyped with different envelopes (vesicular stomatit

258 neutralization of vesicular stomatitis virus pseudotyped with Ebola virus GP.

259 r envelope proteins replaced with EBOV GP or pseudotyped with EBOV GP.

260 Viruses pseudotyped with env clones representative of each mater

261 1b, as well as neutralization of lentivirus pseudotyped with HCV 1a and 1b envelope glycoproteins.

262 from these antibodies, retrovirus particles pseudotyped with HCV glycoproteins (HCVpp) isolated from

263 neutralized a panel of retroviral particles pseudotyped with HCV glycoproteins from six genotypes an

264 and, as negative controls, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or m

265 ted vesicular stomatitis virus (VSV) virions pseudotyped with HSV-1 essential entry glycoproteins gB,

266 ected cells, inhibited entry of retroviruses pseudotyped with Marburg virus GP(1,2), as well as Marbu

267 The infectivity of HIV-1 pseudotyped with murine leukemia virus (MLV) Env was not

268 ion of human T cells by HIV reporter viruses pseudotyped with R5-tropic gp120 envelope proteins but h

269 of compounds for blocking of entry of HIV-1 pseudotyped with SARS-CoV surface glycoprotein S (SARS-S

270 The ability to generate viral particles pseudotyped with SARS-COV-2 Spike is useful for many typ

271 Finally, HIV-1 particles pseudotyped with SARS-COV-2 Spike were successfully used

272 to selectively bind to retroviral particles pseudotyped with SARS-S.

273 By contrast, viruses pseudotyped with subtype A and C Env proteins were able

274 Virus pseudotyped with subtype B Env showed robust entry via C

275 Hepatitis D virus particles pseudotyped with surface proteins of U. bilobatum HBV, b

276 activity, with mammalian retroviral vectors pseudotyped with the ASLV-A envelope glycoprotein (EnvA)

277 Lentiviruses (LVs) pseudotyped with the chimeric GPs were evaluated in term

278 tor signaling, enhanced the entry of viruses pseudotyped with the glycoprotein of lymphocytic choriom

279 cycle simian immunodeficiency viruses (SIVs) pseudotyped with the glycoprotein of vesicular stomatiti

280 imaged fusion of single retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G

281 s effect was not observed with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycopro

282 the infectious entry of lentiviral particles pseudotyped with the wild-type or furin cleavage site-de

283 y of lentiviral and gamma-retroviral vectors pseudotyped with various envelope glycoproteins.

284 HD5 and HD6 promoted HIV reporter viruses pseudotyped with vesicular stomatitis virus and murine l

285 upon infection of mouse DCs with HIV-1 cores pseudotyped with vesicular stomatitis virus G protein.

286 the Moloney murine leukemia retrovirus (MLV) pseudotyped with vesicular stomatitis virus glycoprotein

287 e for HSPC transduction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoprotein

288 lycoprotein S (SARS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glyc

289 VBIM virus particles are pseudotyped with VSV G protein, allowing efficient infec

290 T cells with lentiviral particles that were pseudotyped with VSV-G or CXCR4-tropic HIV Env and assay

291 an immunodeficiency chimeric virus particles pseudotyped with XMRV envelope protein were used to demo

292 of a green fluorescent protein (GFP) vector pseudotyped with XMRV produced GFP(+) CD4(+) T cells and

293 he host protein CD4, which efficiently forms pseudotypes with VSV envelopes.

294 ly developed targeting lentiviral vectors by pseudotyping with modified Sindbis virus envelope protei

295 nd confocal microscopy, we demonstrated that pseudotyping with rabies virus envelope glycoprotein (RV

296 rotrophin receptor), thus demonstrating that pseudotyping with RV-G targets lentiviral vectors for tr

297 In vivo, lentiVLP pseudotyping with the gp160 envelope or with a combinati

298 Remarkably, pseudotyping with the HAdV-5 fiber and/or penton RGD loo

299 , the polytropic MuLV genome was extensively pseudotyped within ecotropic virions; polytropic virus r

300 f complete endogenous retrovirus genomes via pseudotyping within exogenous retroviral virions.